Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.

E. H. Estey; H. M. Kantarjian; M. Beran; K. B. McCredie; M. J. Keating; A. Deisseroth; J. U. Gutterman

doi:10.1007/978-3-642-74643-7_134

Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.

E. H. Estey, H. M. Kantarjian, M. Beran, K. B. McCredie, M. J. Keating, A. Deisseroth, J. U. Gutterman

Leukemia

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

We gave 4 days of high-dose Ara-C followed 2 days later by rHUGM-CSF (which continued until the neutrophil count was greater than 1000/microliters) to 12 patients with newly diagnosed AML and a relatively poor prognosis. Six CRs occurred, there were four deaths during induction, and in only one case was there an rHUGM-CSF-associated growth of leukemia. The pattern of hematologic recovery was variable but in some patients rHUGM-CSF seemed to accelerate normal myelopoiesis following chemotherapy. Continued investigation of rHUGM-CSF and chemotherapy in AML is warranted.

Original language	English (US)
Pages (from-to)	732-736
Number of pages	5
Journal	Haematology and blood transfusion
Volume	33
DOIs	https://doi.org/10.1007/978-3-642-74643-7_134
State	Published - 1990

Access to Document

10.1007/978-3-642-74643-7_134

Cite this

@article{4e33c8910f79404ba8e6b6e27100ffdc,

title = "Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.",

abstract = "We gave 4 days of high-dose Ara-C followed 2 days later by rHUGM-CSF (which continued until the neutrophil count was greater than 1000/microliters) to 12 patients with newly diagnosed AML and a relatively poor prognosis. Six CRs occurred, there were four deaths during induction, and in only one case was there an rHUGM-CSF-associated growth of leukemia. The pattern of hematologic recovery was variable but in some patients rHUGM-CSF seemed to accelerate normal myelopoiesis following chemotherapy. Continued investigation of rHUGM-CSF and chemotherapy in AML is warranted.",

author = "Estey, {E. H.} and Kantarjian, {H. M.} and M. Beran and McCredie, {K. B.} and Keating, {M. J.} and A. Deisseroth and Gutterman, {J. U.}",

note = "Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine",

year = "1990",

doi = "10.1007/978-3-642-74643-7_134",

language = "English (US)",

volume = "33",

pages = "732--736",

journal = "Haematology and blood transfusion",

issn = "0171-7111",

}

TY - JOUR

T1 - Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.

AU - Estey, E. H.

AU - Kantarjian, H. M.

AU - Beran, M.

AU - McCredie, K. B.

AU - Keating, M. J.

AU - Deisseroth, A.

AU - Gutterman, J. U.

N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

PY - 1990

Y1 - 1990

N2 - We gave 4 days of high-dose Ara-C followed 2 days later by rHUGM-CSF (which continued until the neutrophil count was greater than 1000/microliters) to 12 patients with newly diagnosed AML and a relatively poor prognosis. Six CRs occurred, there were four deaths during induction, and in only one case was there an rHUGM-CSF-associated growth of leukemia. The pattern of hematologic recovery was variable but in some patients rHUGM-CSF seemed to accelerate normal myelopoiesis following chemotherapy. Continued investigation of rHUGM-CSF and chemotherapy in AML is warranted.

AB - We gave 4 days of high-dose Ara-C followed 2 days later by rHUGM-CSF (which continued until the neutrophil count was greater than 1000/microliters) to 12 patients with newly diagnosed AML and a relatively poor prognosis. Six CRs occurred, there were four deaths during induction, and in only one case was there an rHUGM-CSF-associated growth of leukemia. The pattern of hematologic recovery was variable but in some patients rHUGM-CSF seemed to accelerate normal myelopoiesis following chemotherapy. Continued investigation of rHUGM-CSF and chemotherapy in AML is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0025028185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025028185&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-74643-7_134

DO - 10.1007/978-3-642-74643-7_134

M3 - Article

C2 - 2182463

AN - SCOPUS:0025028185

SN - 0171-7111

VL - 33

SP - 732

EP - 736

JO - Haematology and blood transfusion

JF - Haematology and blood transfusion

ER -

Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.

Abstract

Access to Document

Other files and links

Fingerprint

Cite this